Larimar Therapeutics Inc Sustainability Reports
A clinical-stage biotechnology company focused on developing treatments for complex rare diseases. Its primary asset is nomlabofusp, an investigational frataxin replacement therapy for Friedreich's ataxia.
Sector: Manufacturing
Country: United States
Exchange: Nasdaq
LEI: 529900NCBZHTTJV6HX73
FIGI: BBG001V0GD97
1 reports from 2023 to 2023
